top of page

CodeCheck™ Cell-free DNA Kit

Introduction

Cell-free DNA Quantitative Detection Kit is a duplex fluorescence PCR which incorporates a novel technology with an internal standard for the quantitative detection of plasma DNA. Research by Prof. Pan from the Department of Laboratory Medicine of the First Affiliated Hospital of Nanjing Medical University, China, found that the level of plasma DNA is an indicator, and sensitively reflects the damage of tissues and organs and its severity.

 

The combination of the unique design of primers and probes and the internal parameters solved the issues in traditional quantitative detection for plasma DNA regarding poor accuracy and stability. Through the real-time dynamic monitor of abnormal cell death, the quantitative measurement could play a crucial role in the assessment of patients' illness severity, treatment efficacy monitoring and prognosis.

 

This device with breakthrough technology is used as an aid to assist doctors to decide which patients and when should be treated with more aggressive interventions, as a result to improve the cure rate and lower the mortality rate. 

During the earlier research, this technology had been applied on various common clinical severe diseases, including acute infection, trauma, organ failure, and drug side effects, for the use of a quick assessment, condition dynamic monitoring, treatment monitoring, and precision diagnosis and treatment guidance.

The cfDNA quantification level is to be used by healthcare providers as an indicator to predicate the severity of illness and to provide timely intervention. The level of cell-free DNA in human plasma is a direct indicator reflecting the tissue and organ damage. 

DISCLAIMER: THE KIT CURRENTLY IS NOT COMMERCIALLY AVAILABLE FOR SELL OR TO BE DISTRIBUTE FOR RESEARCH USE ONLY OR IN-VITRO DIAGNOSIS USE ONLY IN ANY FORMAT. ANY THIRD PARTY PRESENT OR LIST USING THE INFORMATION FOR COMMERCIAL PURPOSE WITHOUT THE PERMISSION OR LICENSE IS AGAINST THE AUTHOR'S RIGHTS, REGARDLESS OF FORMAT (PAPER, AUDIOVISUAL, PLASTIC, ONLINE ETC.).

Overviews

6372800893634576518626970.jpg

Selected Publications

Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
Pan S, Xia W, Ding Q, et al. Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?. Biomed Pharmacother. 2012;66(2):131-137. doi:10.1016/j.biopha.2011.11.022
https://www.sciencedirect.com/science/article/abs/pii/S0753332212000133
Study of quantitative detection of circulating DNA in the plasma of patients with cervical lesion
Wang H, Pan SY, Xu J, et al. Zhonghua Fu Chan Ke Za Zhi. 2011;46(7):501-504.
https://pubmed.ncbi.nlm.nih.gov/22041441/
Methylation quantification of adenomatous polyposis coli (APC) gene promoter in plasma of lung cancer patients
Pan SY, Xie EF, Shu YQ, et al. Ai Zheng. 2009;28(4):384-389.
https://pubmed.ncbi.nlm.nih.gov/19622298/
Development and Evaluation of a Duplex Real-Time PCR Assay With a Novel Internal Standard for Precise Quantification of Plasma DNA
Chen D, Pan S, Xie E, Gao L, Xu H, Xia W, Xu T, Huang P. Development and Evaluation of a Duplex Real-Time PCR Assay With a Novel Internal Standard for Precise Quantification of Plasma DNA. Ann Lab Med. 2017;37:18–27. [PMC free article] [PubMed] [Google Scholar]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107613/
Value of dynamic plasma cell-free DNA monitoring in septic shock syndrome: A case report
Liu JP, Zhang SC, Pan SY. Value of dynamic plasma cell-free DNA monitoring in septic shock syndrome: A case report. World J Clin Cases. 2020;8(1):200-207. doi:10.12998/wjcc.v8.i1.200
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962064/
Page 1 of 1

CIBG letter and Declaration of Conformity

bottom of page